Cybin Inc. (NASDAQ:HELP – Get Free Report)’s share price fell 7.7% during trading on Tuesday. The company traded as low as $7.31 and last traded at $7.0820. Approximately 489,730 shares changed hands during trading, a decline of 63% from the average session volume of 1,330,713 shares. The stock had previously closed at $7.67.
Analyst Ratings Changes
Several equities analysts have weighed in on HELP shares. TD Cowen increased their target price on Cybin from $8.00 to $62.00 and gave the company a “buy” rating in a research note on Thursday, August 20th. Wells Fargo & Company boosted their target price on Cybin from $16.00 to $22.00 and gave the stock an “overweight” rating in a research report on Thursday, October 22nd. Barclays began coverage on Cybin in a research note on Friday, September 18th. They issued an “overweight” rating and a $35.00 price target for the company. Finally, Wall Street Zen downgraded shares of Cybin from a “sell” rating to a “strong sell” rating in a research report on Saturday, November 7th. Six analysts have rated the stock with a Buy rating. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $47.33.
Check Out Our Latest Report on HELP
Cybin Trading Down 3.9%
The firm’s fifty day moving average price is $11.15 and its 200-day moving average price is $7.81. The company has a market cap of $588.28 million, a price-to-earnings ratio of -2.46 and a beta of 0.64.
Cybin (NASDAQ:HELP – Get Free Report) last issued its quarterly earnings data on Friday, November 13th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.74). As a group, research analysts anticipate that Cybin Inc. will post -2.95 EPS for the current year.
Insiders Place Their Bets
In other Cybin news, CFO Greg Cavers purchased 3,000 shares of the company’s stock in a transaction dated Tuesday, September 29th. The shares were bought at an average price of $12.91 per share, with a total value of $38,730.00. Following the completion of the transaction, the chief financial officer directly owned 3,000 shares in the company, valued at $38,730. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Eric H. L. So purchased 100,000 shares of the company’s stock in a transaction dated Tuesday, September 8th. The shares were acquired at an average cost of $12.39 per share, for a total transaction of $1,239,000.00. Following the transaction, the insider owned 4,465,014 shares of the company’s stock, valued at $55,321,523.46. This trade represents a 2.29% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased 688,000 shares of company stock valued at $8,422,830 over the last ninety days. 15.00% of the stock is owned by insiders.
Institutional Trading of Cybin
Several hedge funds have recently bought and sold shares of HELP. Goldman Sachs Group Inc. acquired a new position in shares of Cybin in the third quarter valued at approximately $568,000. Great Point Partners LLC acquired a new stake in shares of Cybin during the third quarter worth $3,944,000. Integral Health Asset Management LLC bought a new stake in Cybin in the 3rd quarter valued at $6,145,000. Blue Owl Capital Holdings LP lifted its position in Cybin by 381.2% in the 3rd quarter. Blue Owl Capital Holdings LP now owns 288,282 shares of the company’s stock valued at $3,543,000 after acquiring an additional 228,371 shares in the last quarter. Finally, State Street Corp bought a new stake in Cybin in the 3rd quarter valued at $363,000. 17.94% of the stock is currently owned by institutional investors and hedge funds.
Cybin Company Profile
Cybin, which changed its name to Helus Pharma, is a clinical-stage biopharmaceutical company developing psychedelic-based treatments for mental health conditions. Its research focuses on designing and evaluating investigational compounds intended to address conditions including depression and anxiety disorders. The company’s pipeline has included CYB003, a deuterated psilocin analog being studied for major depressive disorder, and CYB004, an investigational DMT-based treatment studied for generalized anxiety disorder.
See Also
- Five stocks we like better than Cybin
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
